![](https://bloximages.newyork1.vip.townnews.com/wfmz.com/content/tncms/assets/v3/editorial/4/1a/41a23995-c461-5cd9-9720-ff051dd22ce4/67ab82c80b43d.image.jpg?crop=572%2C572%2C0%2C29&resize=200%2C200&order=crop%2Cresize)
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Approved in Thailand
NERLYNX® (neratinib) has been approved as a single agent for the treatment of early-stage HER2+ breast cancer, and in combination with capecitabine for the treatment of advanced or metastatic HER2+ breast cancer[1] Approval coincides with the first …